Submitted by Jeffrey Lake on Thu, 10/06/2016 - 1:59pm Please indicate your specialization * Hepatologists Gastroenterologists Endocrinologist General practitioner Other... Please indicate your specialization Other... How familiar are you with the Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS), which is used to define and quantify disease activity? * Very familiar, I have a complete understanding of what NAS consists Familiar, I have a basic understanding of the score I have heard of NAS, but cannot recall the specifics Not familiar How confident are you in the staging of liver fibrosis? * Very confident Confident Reasonably confident, I would like to learn more Not very confident, I should learn more How familiar are you with the key endpoints used in clinical trials investigating emerging novel therapies for NASH? * Very familiar, I have a complete knowledge of these endpoints such as “resolution of NASH with no worsening of fibrosis” or “improvement of at least one stage of liver fibrosis with no worsening of NASH” Familiar, I have a basic understanding of these endpoints such as “resolution of NASH with no worsening of fibrosis” or “improvement of at least one stage of liver fibrosis with no worsening of NASH” I have heard of these endpoints, but cannot recall the specifics Not familiar If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following: First Name: Last Name: Email: Leave this field blank
